EUCTR2005-001138-33-LT进行中（未招募）不适用
A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •2.Patients with rheumatoid arthritis of greater than or equal to 3 months duration diagnosed according to the revised 1987 American College of Rheumatology (ACR; formerly American Rheumatism Association) criteria (Appendix 2).
- •3.Receiving treatment on an outpatient basis.
- •4.Prior to randomization, will have discontinued etanercept for greater than or equal to 2 weeks, infliximab or adalimumab for greater than or equal to 8 weeks (see exclusion # 7), anakinra for greater than or equal to 1 week, leflunomide for > 12 weeks (or greater than or equal to 4 weeks after 11 days of standard cholestyramine washout).
- •5.All DMARDs withdrawn prior to baseline.
- •6.Swollen joint count (SJC) greater than or equal to 6 (66 joint count) and tender joint count (TJC) greater than or equal to 8 (68 joint count) at screening and baseline.
- •7.At screening either CRP greater than or equal to 1 mg/dL (10 mg/L) or ESR less than or equal to 28 mm/hr
- •8.Age greater than or equal to 18 years
- •9.Oral corticosteroids (less than or equal to 10 mg/day prednisone or equivalent) and NSAIDs (up to the maximum recommended dose) are permitted if the dose has been stable for at least 6 weeks prior to baseline.
- •10.Females of child-bearing potential and males with female partners of child-bearing potential may participate in this trial only if using a reliable means of contraception (e.g. physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or IUD).
- •11.If female and of childbearing potential, the patient must have a negative urine pregnancy test within three weeks prior to baseline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Major surgery (including joint surgery) within eight weeks prior to screening or planned surgery within six months following randomization.
- •2.Rheumatic autoimmune disease other than RA, including SLE, MCTD, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty’s syndrome). Sjögren’s Syndrome with RA is allowable.
- •3.Functional class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis (Appendix 3)
- •4.Prior history of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease).
- •Excluded Previous or Concomitant Therapy:
- •5.Treatment with MTX within 6 months prior to randomization.
- •6.Discontinued previous MTX treatment as a result of clinically important toxic effects or lack of response as determined by the investigator.
- •7.Unsuccessful treatment with an anti-TNF agent (i.e. significant safety issues or lack of efficacy; Patients who terminated previous anti-TNF treatment due to cost or discomfort with the subcutaneous injections, may participate in this study.) (See Inclusion #4 for anti-TNF agent washouts.)
- •8.Treatment with any investigational agent within four weeks (or five half-lives, whichever is longer) of screening.
- •9.Previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20).
- •10.Treatment with intravenous gamma globulin, plasmapheresis or Prosorba ? column within six months of baseline.
- •11.Intra-articular or parenteral corticosteroids within six weeks prior to baseline.
- •12.Immunization with a live/attenuated vaccine within four weeks prior to baseline.
- •13.Previous treatment with MRA (an exception to this criterion may be granted for single dose exposure upon application to the sponsor on a case by case basis).
- •14.Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
- •Exclusions for General Safety
- •15.History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
- •16.Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (incl. obstructive pulmonary disease), renal, hepatic, endocrine (incl. uncontrolled diabetes mellitus) or gastrointestinal disease.
- •17.Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids.
- •18.Current liver disease as determined by principal investigator. (Patients with prior history of ALT elevation will not be excluded.)
- •19.Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, granulomatous disease on chest X-ray, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within four weeks of screening or oral antibiotics within two weeks prior to screening.
- •20.Primary or secondary immunodeficiency (history of or currently active).
- •21.History of malignancy, including solid tumors and hematologic malignancies (except basal cell carcinoma of the skin that has been excised and cured).
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinibMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2020-005929-89-PLovartis Pharma AG800
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2015-005419-33-HUovartis Pharma Services AG1,313
未知
3 期
A randomized, double-blind, double-dummy, parallel group, active controlled multi-center clinical trial to evaluate the additional efficacy and safety of Olmesartan Medoxomil/Amlodipine 20/5 mg in Chinese patients with mild or moderate essential hypertension who failed to achieve their goal with Olmesartan Medoxomil 20mg monotherapyEssential HypertensionJPRN-jRCT2080221543Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.252
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosismultiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005419-33-DEovartis Pharma Services AG1,313
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosismultiple sclerosisMedDRA version: 19.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005418-31-GRovartis Pharma AG900